New Ferring and Aché Laboratórios Farmacêuticos Facility Opens to Optimise Drug Delivery Using Nanotechnology
Ferring Pharmaceuticals and Aché Laboratórios Farmacêuticos today announced the inauguration of their joint nanotechnology centre in São Paulo, Brazil. Focused exclusively on nanotechnology research and development, the centre forms the first phase in a long term collaboration to optimise patient care through enhanced drug delivery systems and product solutions.
The Nanotechnology Innovation Laboratory Enterprise (NILE) centre and associated research programme will explore nanotechnology to advance the delivery characteristics of existing medicines, create novel devices and find new formulations for poorly soluble drugs. For example, for patients who currently receive treatment by injection, this new technology has the potential to transform their ongoing care with new oral options. Researchers will investigate how nanotechnology might improve the bioavailability, efficacy and safety profile of oral medicines, and alleviate any unwanted toxicity resulting from non-specific distribution.
Initial research projects will utilise each company’s therapeutic strengths. Ferring will provide expertise on peptides and proteins in reproductive medicine and women’s health, gastroenterology and urology, and Aché will provide knowledge on how to expedite the development of new therapeutic entities with different technical properties.
“Using nanotechnology to administer peptide and protein-based medicines orally could be a significant step forward for the ease of delivery for this important class of drugs,” said Alan Harris, Senior Vice President, R&D, Ferring Pharmaceuticals. “Ferring’s pioneering work in reproductive medicine and women’s health is devoted to providing next generation solutions that improve outcomes and better serve the needs of our patients. If we can provide patients with more convenient dosing, we will help to improve adherence and ensure that patients receive the greatest benefit from treatment.”
“In recent years, considerable investment has been made in Brazil to harness the potential of nanotechnology. Our established strength in using radical innovation to create new assets, whether synthetic, herbal, biologicals or nutraceuticals, combined with the rich source of natural compounds existing within Brazilian biodiversity, places us in a unique position to lead future cutting-edge science,” said Stephani Saverio, head of Innovation of Aché. “Nanotechnology has huge potential to address the challenges associated with today’s drug delivery systems and to optimise future care.”
The NILE centre is anticipated to be a global hub for future drug discovery and development. The inauguration ceremony brought together leading experts from the field of nanotechnology as well as dignitaries from the Ministry of Health of Brazil and government officials.
- Ends -
About Nanotechnology
Nanotechnology is a branch of
technology focused on understanding and controlling matter at the very
smallest scales. At nanoscale, properties can be very different when
compared to those with which we are familiar. Such properties mean that
nanotechnology has the potential to optimise current drug delivery
technologies, and offers many opportunities to create new drug delivery
systems, formulations for poorly soluble drugs and novel devices. In
addition to the potential advantages of enhancing systemic
administration, nanoparticulate drug delivery systems can also be used
for site-specific delivery, thus alleviating unwanted toxicity due to
nonspecific distribution, helping to improve patient compliance and
provide favourable clinical outcomes. Nanotechnology platforms will help
in the development of advanced drug-delivery systems to decrease the
failure rate of new active pharmaceutical ingredients (APIs),
bio-therapeutic agents and vaccines caused by poor absorption, or
distribution, significant drug toxicity, and rapid metabolism or
excretion.
About Ferring Pharmaceuticals:
Headquartered in Saint-Prex,
Switzerland, Ferring Pharmaceuticals is a research-driven, specialty
biopharmaceutical group active in global markets. A leader in
reproductive and maternal health, Ferring has been developing treatments
for mothers and babies for over 50 years. Today, over one third of the
company’s research and development investment goes towards finding
innovative treatments to help mothers and babies, from conception to
birth. The company also identifies, develops and markets innovative
products in the areas of urology, gastroenterology, endocrinology and
orthopaedics. Ferring has its own operating subsidiaries in nearly 60
countries and markets its products in 110 countries. For further
information on Ferring or its products, visit www.ferring.com.
Ferring is on Twitter. Follow us @FerringNews at http://twitter.com/FerringNews
About Aché Laboratórios Farmacêuticos
Aché is a 100%
Brazilian company with more than 50 years of operation in the
pharmaceutical market with the objective of bringing more life to the
persons, wherever they are. It has three industrial sites: Guarulhos
(SP), São Paulo (SP), and Londrina (PR), and participation in Melcon do
Brasil, and Bionovis, a Brazilian joint venture dedicated to research
and development of biotechnology medicines. It employs 4,600 people and
has one of the largest demand and sales generation forces in the
pharmaceutical sector in Brazil. In order to meet the needs of
healthcare professionals and consumers, Aché offers a portfolio of 326
brands in 804 submissions for prescription, generic and OTC
(non-prescription) drugs, and it also acts in the segments of skin
cosmetics, nutraceuticals, probiotic and biological segments. Ache´s
focus on innovation has been developing attractive products currently
present in 20 countries of the Americas, Africa, and Asia. Ache´s
innovative products are being developed for registration in the world´s
most regulated markets. To know more about Aché, please visit www.ache.com.br.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: http://www.businesswire.com/news/home/20171129005641/en/
Contact information
Ferring Corporate Communications Team:
Lindsey Rodger
Senior
Manager, Corporate Communications
+41 58 451 4023 (direct)
+41
79 191 0486 (mobile)
lindsey.rodger@ferring.com
or
Bhavin
Vaid
Head of Corporate Communications
+41 58 301 0952 (direct)
+41
79 191 0632 (mobile)
bhavin.vaid@ferring.com
or
For
Aché Laboratórios Farmacêuticos
Press
Information:
CDI Corporative Communication
Renata
Lopes
+55 (11) 3817-7994
renata.lopes@cdicom.com.br
or
Flavia
Tavares
+55 (11) 3817-7914
flavia@cdicom.com.br
or
Cláudia
Santos
+55 (11) 3817-7925
claudia@cdicom.com.br
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SBC Medical added to membership of Russell 3000 ® Index28.6.2025 02:30:00 EEST | Press release
SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical”), a global franchise and provider of services for aesthetic clinics, has been added as a member of the broad-market Russell 3000® Index, effective after the US market opens on June 30, as part of the 2025 Russell indexes reconstitution. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250608244276/en/ Yoshiyuki Aikawa-Director (Chairman), CEO Membership in the Russell 3000® Index, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000® Index or small-cap Russell 2000®Index as well as the appropriate growth and value style indexes. Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. According to the data as of the end of June 2024, about $10.6 trillion in assets are benchmarked against the Russell US indexes, which belong to
Altimetrik and SLK Software Join Forces to Create an AI-First Engineering Services Powerhouse27.6.2025 23:44:00 EEST | Press release
Altimetrik, a pure-play AI, Data and Digital engineering solutions company, today announced the signing of a definitive agreement to acquire SLK Software (“SLK”), a global technology services firm focused on delivering AI, intelligence automation and analytics solutions. The acquisition will further strengthen Altimetrik’s end-to-end enablement services and expand its customer reach, with a clear path to accelerate towards Altimetrik’s goal of reaching $1billion in annual revenue. The transaction remains subject to customary closing conditions and is expected to close in the second half of 2025. Financial details were not disclosed. Founded in 2000, SLK is recognized as a leader in the tech industry, and for its commitment to create innovative digital solutions. This strategic acquisition will significantly enhance the scale of Altimetrik’s capabilities, bringing together Altimetrik’s AI-first, platform-native engineering model and SLK’s full technology services stack that will further
PRD Therapeutics Announces Initiation of First-in-Human Study for PRD00127.6.2025 17:00:00 EEST | Press release
PRD Therapeutics, Inc., a clinical stage company focused on the development of novel lipid metabolism regulators targeting homozygous familial hypercholesterolemia (HoFH) and metabolic dysfunction associated fatty liver disease (MASH/MASLD), today announced that the company recently initiated dosing in a First-in-Human (FIH) clinical trial of PRD001, a first-in-class SOAT2 (formerly known as ACAT2) selective inhibitor. “We are excited to initiate dosing in this clinical trial of PRD001. Many clinical trials have been conducted on SOAT1/2 dual or SOAT1 selective inhibitors, but this is the first clinical trial of an SOAT2 selective inhibitor” said Kanji Hosoda, Ph.D., CEO and co-founder of PRD Therapeutics. “Several results with SOAT1 or 2 knockout mice have been published, suggesting that knocking out or inhibiting only SOAT2 is crucial to demonstrate safety and efficacy. PRD001 is the world's first and only SOAT2-selective inhibitor and is expected to exhibit safety and efficacy in hu
STEMCELL Technologies Introduces STEMprep™ Tissue Dissociator System to Accelerate Research Discoveries27.6.2025 15:00:00 EEST | Press release
To help scientists accelerate their workflows, STEMCELL Technologies has commercially launched the STEMprep™ Tissue Dissociator System—a new benchtop instrument that automates, standardizes, and streamlines tissue dissociation, the process of breaking down tissue samples into single-cell suspensions for research purposes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250627342791/en/ To help scientists accelerate their workflows, STEMCELL Technologies has commercially launched the STEMprep™ Tissue Dissociator System—a new benchtop instrument that automates, standardizes, and streamlines tissue dissociation, the process of breaking down tissue samples into single-cell suspensions for research purposes. “Tissue dissociation is incredibly important for making advancements in research fields, like cancer and immunology, yet this manual process demands significant time and effort and can lead to inconsistent results,” said Dr. A
Pure Lithium Founder & CEO Emilie Bodoin Recognized for Trailblazing Woman of the Year at 2025 Volta Foundation Awards at 17 th Annual Fastmarkets Lithium Supply and Battery Raw Materials Conference27.6.2025 13:00:00 EEST | Press release
Pure Lithium Corporation, a disruptive vertically integrated lithium metal battery technology company, is pleased to announce that its Founder, Chairman & CEO, Emilie Bodoin received special recognition for Trailblazing Woman of the Year Award Sponsored by ExxonMobil at the 2025 Fastmarkets Volta Awards Ceremony, in Las Vegas, Nevada on June 24. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250627170164/en/ This award celebrates an exceptional female leader who has demonstrated outstanding leadership, vision, and impact within her industry. It recognizes achievements in driving innovation, fostering diversity, and inspiring others while making significant contributions to her organization. “I am truly honored to receive special recognition for this award. One of the best things about my role is the opportunity to lead by example and encourage and inspire women and girls who may not yet recognize their potential. To all of m
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom